Keith Flaherty
Keith Flaherty is Director of Clinical Research at the Massachusetts General Hospital Cancer Center and Professor of Medicine at Harvard Medical School.[1] He was previously a professor of medicine at the University of Pennsylvania. He is known for his research on targeted therapies for cancer, and in particular for his work on the melanoma drug vemurafenib.[2][3][4][5] In 2013, Massachusetts General Hospital partnered with AstraZeneca to partner Flaherty's research into developing a formula to identify vulnerabilities of tumors with AstraZeneca's library of drugs.[6]
References
[edit]- ↑ Keith T. Flaherty, MD - Massachusetts General Hospital, Boston, MA
- ↑ Target Cancer - A Roller Coaster Chase for a Cure - Series - NYTimes.com
- ↑ Target Cancer - After Long Fight, Melanoma Drug Gives Sudden Reprieve - Series - NYTimes.com
- ↑ Target Cancer - A Drug Trial Cycle - Recovery, Relapse, Reinvention - Series - NYTimes.com
- ↑ Inhibition of Mutated, Activated BRAF in Metastatic Melanoma — NEJM
- ↑ Weintraub, Karen (19 May 2013). "MGH, AstraZeneca partner to create new drug combos". Boston Globe. Archived from the original on 8 April 2015. Retrieved 30 January 2015.
| Authority control databases: Academics |
|---|
